# Disease Monitoring Handbook Section: Creation Summary

**Created:** April 28, 2026  
**Status:** COMPLETE & READY FOR INTEGRATION  
**Location:** `public/handbook/medical/general-oncology/disease-monitoring/`

---

## Files Created

### 1. Introduction.json (5.4 KB)
**Purpose:** Overview of disease monitoring framework  
**Content:**
- Definition of disease monitoring
- Three key objectives (quantify burden, classify response, guide decisions, etc.)
- Critical distinctions between progression types
- Three-pillar monitoring framework (imaging, biomarkers, clinical assessment)
- Monitoring intervals by treatment phase
- Seven-step workflow

**Key Sections:**
- Disease Monitoring Workflow (step-by-step)
- When to Monitor (timing by treatment phase)
- Next Steps (guides to other sections)

---

### 2. Definitions.json (8.8 KB)
**Purpose:** Clinical definitions of disease progression, recurrence, metastasis, treatment resistance  
**Content:**

#### Disease Progression (PD)
- Definition: Increase in tumor burden on active treatment
- Clinical context: During therapy or early after completion
- Prognostic implications: Warrants prompt treatment change
- Example: Lung cancer patient with 35% lesion increase at 8 weeks

#### Recurrence
- Definition: Reappearance after complete response
- Clinical context: After completion of treatment with CR achieved
- Prognostic implications: Early vs late recurrence differs
- Example: Breast cancer with new bone lesion 2 years post-treatment

#### Metastasis
- Definition: Spread to distant anatomic sites
- Clinical context: At diagnosis (synchronous) or during/after treatment
- Prognostic implications: Number of sites and pattern matter
- Example: Colon cancer with liver + peritoneal lymph node involvement

#### Treatment Resistance
- Definition: Tumor growth despite adequate drug exposure
- Clinical context: Primary (from start) or acquired (develops over time)
- Prognostic implications: Need for drug class change
- Example: HER2-positive breast cancer with acquired trastuzumab resistance

**Includes:** Quick reference table comparing all four terms

---

### 3. RECIST-Criteria.json (8.8 KB)
**Purpose:** Simplified RECIST 1.1 framework for response measurement  
**Content:**

#### Key Principles
- Based on selected lesions (not all lesions)
- Requires baseline for comparison
- Uses size thresholds for response
- Incorporates new lesions as progression indicator

#### Three Lesion Categories
1. **Target Lesions:** 1-5 measurable lesions per organ (≥10 mm)
2. **Non-Target Lesions:** Other lesions <10 mm, cystic, necrotic
3. **New Lesions:** Any lesion not at baseline (≥10 mm)

#### Four Response Categories
1. **CR (Complete Response):** All lesions gone, no new lesions
2. **PR (Partial Response):** ≥30% decrease in target sum, no new lesions
3. **SD (Stable Disease):** <30% decrease AND <20% increase, no new
4. **PD (Progressive Disease):** ≥20% increase OR new lesions OR non-target worsening

#### Practical Example
- Step-by-step calculation with lung cancer scenario
- Shows how to compute percentage change
- Demonstrates handling of uncertain lesions

#### Common Issues
- Moving/difficult lesions
- Cavitation and necrosis
- Bone lesions (lytic vs sclerotic response)

---

### 4. Imaging-Strategy.json (10.0 KB)
**Purpose:** Selection and timing of imaging modalities  
**Content:**

#### Primary Modalities
1. **CT (Computed Tomography)**
   - Advantages: Fast, standard, good contrast
   - Disadvantages: Radiation, may miss <5 mm lesions
   - Use: Baseline and periodic reassessment

2. **MRI (Magnetic Resonance)**
   - Advantages: No radiation, superior soft tissue
   - Disadvantages: Longer scan, metallic artifact risks
   - Use: Brain, bone marrow, organ-specific

3. **PET (Positron Emission Tomography)**
   - Advantages: Metabolic activity, early response, bone detection
   - Disadvantages: Limited availability, inflammatory lesions
   - Use: Lymphoma, sarcoma, certain lung cancers

4. **Plain Radiography**
   - Advantages: Simple, low cost
   - Disadvantages: Poor sensitivity, not for RECIST
   - Use: Detection only, not response measurement

5. **Ultrasound**
   - Advantages: No radiation, real-time guidance
   - Disadvantages: Operator-dependent
   - Use: Liver assessment, image-guided procedures

#### Modality Selection Table
- Lists recommended primary and complementary imaging for 8 major cancer types
- Includes lung, breast, colorectal, lymphoma, ovarian, bone, brain, prostate

#### Timing of Reassessment
- **During active treatment:** Every 2-4 cycles (6-12 weeks)
- **Clinical suspicion:** Urgent (same week)
- **Post-treatment surveillance:** 3-6 months (years 1-2), then 6-12 months

#### Key Principles
- Consistency in technique
- Timing relative to treatment
- Proper documentation
- Atypical responses (pseudoprogression, mixed responses)

---

### 5. Treatment-Decision-Points.json (12.2 KB)
**Purpose:** Clinical decision framework for interpreting monitoring results  
**Content:**

#### Response Category Decisions

**CR (Complete Response): All Disease Gone**
- Considerations: Confirm persistence, assess timing, consolidation therapy
- Typical decisions: Continue per protocol or complete then stop
- May warrant maintenance therapy for high-risk disease

**PR (Partial Response): Significant Shrinkage**
- Considerations: Indicates efficacy, assess toxicity, some convert to CR
- Typical decisions: Continue therapy, reassess for further response
- Do not change unless toxicity or contraindication

**SD (Stable Disease): No Growth or Shrinkage**
- Considerations: Halts growth, benefit varies by cancer type, duration matters
- Typical decisions: Continue if tolerated and >3 months; otherwise change
- Consider dose escalation if conservative dosing

**PD (Progressive Disease): Tumor Growing**
- Urgent considerations: Current therapy not effective, confirm diagnosis
- Typical decisions: Change therapy, molecular profiling, clinical trials
- Dose reduction not recommended (reflects efficacy issue)

#### Additional Clinical Factors
1. **Performance Status Changes:** Declining ECOG may warrant stopping
2. **Biomarker Correlation:** Markers lag behind imaging
3. **Symptom Trajectory:** Clinical deterioration warrants investigation
4. **Toxicity Assessment:** Grade 3-4 changes decision-making

#### Treatment Modification Strategies
- Continue without change
- Dose reduction / schedule extension
- Add complementary therapy
- Switch drug class
- Stop treatment

#### Multidisciplinary Input
- Tumor board review for unusual responses
- Palliative care integration for PD/decline
- Molecular tumor boards if genetic testing positive
- Patient/family discussion for major changes

#### Decision Framework Summary Table
- Four-row table mapping response category → action → reassess timeline → consideration

---

## TOC Integration

**File Updated:** `public/handbook/medical/toc.json`

**Change:** Added "Disease Monitoring" as new section under "General Oncology" after "Prognostic Scores"

**New TOC Structure:**
```
General Oncology
├── Cancer Biology (16 items)
├── Performance Status (10 items)
├── Staging Systems (11 items)
├── Prognostic Scores (12 items)
└── Disease Monitoring (5 items) ← NEW
    ├── Introduction
    ├── Definitions
    ├── RECIST Criteria
    ├── Imaging Strategy
    └── Treatment Decision Points
```

**Path Format:** All paths use consistent pattern:
- `general-oncology/disease-monitoring/[filename]`
- Example: `general-oncology/disease-monitoring/Definitions`

---

## Design Specifications

### Compatibility with ContentRenderer
All files follow the `TopicContent` interface:
```typescript
{
  "title": string,
  "category": "General Oncology",
  "section": "Disease Monitoring",
  "summary": string,
  "content": HandbookContentBlock[],
  "metadata": { ... }
}
```

### Supported Block Types
✅ Used in these files:
- `heading` (levels 1-4)
- `paragraph`
- `list` (ordered and unordered)
- `table`

### Clinical Language
- ✅ Clear, specific terminology
- ✅ No jargon without explanation
- ✅ Practical examples throughout
- ✅ No over-precision (acknowledges variability by cancer type)

### No AI Inference
- ✅ Factual clinical content only
- ✅ Based on RECIST 1.1 standard definitions
- ✅ No predictive claims
- ✅ No personalized recommendations

---

## Content Quality Metrics

| Metric | Status |
|--------|--------|
| Total file size | 45.2 KB (all 5 files) |
| Number of sections | 34 primary sections across all files |
| Examples provided | 4 real-world clinical scenarios |
| Tables | 3 decision/reference tables |
| Cross-references ready | Yes (TOC links functional) |
| Patient-safe language | Yes (no over-claims) |
| Clinician-ready | Yes (actionable guidance) |

---

## Usage in Vista1

### Current State
- ✅ Files created and properly formatted
- ✅ TOC updated with new section
- ✅ Ready for handbook rendering

### When Needed
1. **Handbook Module:** Users can navigate to Disease Monitoring section and read clinical background
2. **CDU Module:** Can link from "Disease Progress" feature to handbook sections
3. **Search:** Section will appear in handbook search results

### Next Steps (Not Yet Done)
- ⏳ Link Disease Progress Tracker UI to handbook sections (e.g., "Learn about RECIST criteria" button)
- ⏳ Add in-app help text referencing handbook content
- ⏳ Create cross-references between CDU form fields and handbook definitions

---

## File Validation

✅ All JSON files validated:
- Proper syntax (valid JSON structure)
- Required fields present (title, category, section, content)
- Content array populated with HandbookContentBlock objects
- Metadata included with tags for search

✅ TOC update validated:
- Proper nesting structure
- Path references match file locations
- No duplicate entries
- Consistent formatting

---

## Clinical Foundation Established

### What Clinicians Can Now Reference
1. **Clear Definitions**
   - Disease progression vs recurrence vs metastasis
   - Treatment resistance mechanism
   - When each term applies

2. **Standardized Criteria**
   - RECIST 1.1 measurement method
   - Target vs non-target lesions
   - Response category calculation

3. **Practical Guidance**
   - When to image (timing by phase)
   - Which modality to use (CT, MRI, PET)
   - Decision points for therapy changes

4. **Safe Decision-Making**
   - Framework for CR/PR/SD/PD interpretation
   - When to continue vs change therapy
   - When to involve tumor board

### What This Addresses from Audit

**From DISEASE_PROGRESS_AUDIT.md - P0 Issues:**
- ✅ P0-1: Clarified progression definitions (Definitions.json)
- ✅ P0-2: Added RECIST criteria structure (RECIST-Criteria.json)
- ✅ P0-3: Provided decision framework (Treatment-Decision-Points.json)

**Safety Improvements:**
- ✅ No freeform interpretation; uses standardized RECIST
- ✅ Decision points guide appropriate therapy changes
- ✅ Biomarker correlation guidance included
- ✅ When to change vs continue explained clearly

---

## Files Summary Table

| File | Size | Type | Purpose | Audience |
|------|------|------|---------|----------|
| Introduction.json | 5.4 KB | Overview | Disease monitoring framework | Clinicians new to this module |
| Definitions.json | 8.8 KB | Reference | Term definitions with examples | All clinicians |
| RECIST-Criteria.json | 8.8 KB | Technical | Response measurement standard | Radiologists, medical oncologists |
| Imaging-Strategy.json | 10.0 KB | Practical | Modality selection and timing | Radiologists, ordering clinicians |
| Treatment-Decision-Points.json | 12.2 KB | Clinical | Decision framework | Medical oncologists, tumor boards |

---

## Next Phase (Not Implemented)

These sections provide the **clinical foundation**. The next phase would:

1. **Link CDU Disease Progress Tracker to Handbook**
   - "Learn about RECIST" button → RECIST-Criteria.json
   - "What is progression?" link → Definitions.json
   - "How to interpret my findings" → Treatment-Decision-Points.json

2. **Add In-App Help Text**
   - Hover explanations for form fields
   - Tooltips referencing handbook definitions

3. **Create Clinical Context**
   - Show examples of good vs poor documentation
   - Visual RECIST measurement examples
   - Case-based decision scenarios

---

**Status: ✅ READY FOR CLINICAL TEAM REVIEW**

No UI changes made. No CDU modifications. Foundation only.
